Thiazovivin 5 mg | ≥98% LKT Laboratories, Inc. ROCK inhibitor. More Information Supplier Page × Thiazovivin
Tivantinib 10 mg | ≥98% LKT Laboratories, Inc. MET and GSK-3α/β inhibitor. More Information Supplier Page × Tivantinib
Tivantinib 5 mg | ≥98% LKT Laboratories, Inc. MET and GSK-3α/β inhibitor. More Information Supplier Page × Tivantinib
YM-155 10 mg | ≥98% LKT Laboratories, Inc. Survivin inhibitor. More Information Supplier Page × YM-155
YM-155 5 mg | ≥98% LKT Laboratories, Inc. Survivin inhibitor. More Information Supplier Page × YM-155
SB-203580 25 mg | ≥98% LKT Laboratories, Inc. p38 MAPK inhibitor. More Information Supplier Page × SB-203580
RKI-1447 1 mg | ≥98% LKT Laboratories, Inc. ROCK1/2 inhibitor. More Information Supplier Page × RKI-1447
Nutlin-3 5 mg | ≥98% LKT Laboratories, Inc. Imidzoline derivative; MDM2 inhibitor. More Information Supplier Page × Nutlin-3
Nutlin-3 1 mg | ≥98% LKT Laboratories, Inc. Imidzoline derivative; MDM2 inhibitor. More Information Supplier Page × Nutlin-3
PFI-1 10 mg | ≥98% LKT Laboratories, Inc. Acyl-lysine (Kac) mimetic; BRD2/4 inhibitor. More Information Supplier Page × PFI-1
